



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 17, 2014

Via E-mail

R. Michael Carruthers  
Chief Financial Officer  
Array BioPharma Inc.  
3200 Walnut Street  
Boulder, Colorado 80301

**Re: Array BioPharma, Inc.  
Annual Report on Form 10-K for the fiscal year ended June 30, 2013  
Filed August 12, 2013  
Quarterly Report on Form 10-Q for the quarterly period  
ended December 31, 2013  
Filed February 5, 2014  
File No. 001-16633**

Dear Mr. Carruthers:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

*/s/ Daniel Greenspan for*

Jeffrey P. Riedler  
Assistant Director

cc: Carin M. Cutler, Esq.  
Gross Cutler Seiler DuPont  
1877 Broadway, Suite 601  
Boulder, CO 80302